The Trump administration has finalized rules to prevent drug manufacturers from circumventing Medicare's drug price negotiation process. This new regulation aims to stop companies from resetting negotiation timelines by reformulating their drugs. The Centers for Medicare and Medicaid Services issued the final rule to ensure consistent application of price negotiation. AI
RANK_REASON Significant policy update from a US administration impacting a major healthcare program. [lever_c_demoted from significant: ic=1 ai=0.0]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →